X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (154) 154
humans (141) 141
male (88) 88
female (87) 87
middle aged (82) 82
urology & nephrology (80) 80
aged (69) 69
albuminuria (62) 62
risk factors (62) 62
endocrinology & metabolism (53) 53
diabetes (50) 50
glomerular filtration rate (47) 47
nephropathy (44) 44
glomerular-filtration-rate (43) 43
type 2 diabetes (41) 41
mortality (40) 40
diabetes mellitus (37) 37
adult (36) 36
diabetes mellitus, type 2 - complications (36) 36
blood pressure (34) 34
kidney diseases (34) 34
risk (34) 34
nephrology (33) 33
blood-pressure (32) 32
chronic kidney disease (31) 31
chronic kidney-disease (31) 31
microalbuminuria (31) 31
double-blind method (30) 30
diabetes mellitus, type 2 - drug therapy (29) 29
hypertension (29) 29
treatment outcome (29) 29
diabetic nephropathies - drug therapy (28) 28
clinical trials (27) 27
chronic kidney failure (26) 26
disease progression (26) 26
disease (24) 24
research (24) 24
cardiovascular disease (23) 23
creatinine (23) 23
sodium (23) 23
progression (22) 22
proteinuria (22) 22
biomarkers (21) 21
diabetic nephropathy (20) 20
analysis (19) 19
double-blind (19) 19
cardiovascular diseases (18) 18
patients (18) 18
biomarkers - blood (17) 17
care and treatment (17) 17
diabetes mellitus, type 2 - blood (17) 17
outcomes (17) 17
transplantation (17) 17
abridged index medicus (16) 16
kidneys (16) 16
diabetes mellitus, type 2 - physiopathology (15) 15
diabetic nephropathies - physiopathology (15) 15
follow-up studies (15) 15
kidney-disease (15) 15
medical research (15) 15
population (15) 15
prognosis (15) 15
prospective studies (15) 15
randomized controlled trials as topic (15) 15
studies (15) 15
albuminuria - drug therapy (14) 14
albuminuria - etiology (14) 14
angiotensin (14) 14
biomarkers - urine (14) 14
blood pressure - drug effects (14) 14
complications and side effects (14) 14
diabetic-nephropathy (14) 14
mellitus (14) 14
angiotensin receptor antagonists - therapeutic use (13) 13
association (13) 13
ckd (13) 13
creatinine - urine (13) 13
development and progression (13) 13
diabetic kidney disease (13) 13
diabetic nephropathies (13) 13
drug therapy (13) 13
end-stage renal disease (13) 13
epidermal growth factor receptors (13) 13
hypoglycemic agents - therapeutic use (13) 13
losartan (13) 13
medicine, general & internal (13) 13
peripheral vascular disease (13) 13
renal insufficiency, chronic - physiopathology (13) 13
albumin (12) 12
albuminuria - diagnosis (12) 12
albuminuria - urine (12) 12
antihypertensive agents - therapeutic use (12) 12
cardiac & cardiovascular systems (12) 12
cardiovascular events (12) 12
cohort studies (12) 12
collaborative metaanalysis (12) 12
excretion (12) 12
internal medicine (12) 12
irbesartan (12) 12
kidney - drug effects (12) 12
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, ISSN 0931-0509, 02/2019
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 01/2018, Volume 20, Issue 1, pp. 224 - 227
Individual patients show a large variation in their response to renin‐angiotensin‐aldosteron system ( RAAS ) inhibition ( RAASi ), both in surrogates such as... 
albuminuria | ARB | type 2 diabetes | dapagliflozin | ACEi | sodium‐glucose co‐transporter 2 inhibitor | personalized medicine | sodium-glucose co-transporter 2 inhibitor | ENDOCRINOLOGY & METABOLISM | PROGRESSION | Biomarkers - urine | Humans | Middle Aged | Diabetic Nephropathies - drug therapy | Male | Diabetes Mellitus, Type 2 - metabolism | Hypoglycemia - prevention & control | Diabetic Nephropathies - physiopathology | Renal Insufficiency - physiopathology | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Female | Glucosides - therapeutic use | Renal Insufficiency - complications | Renal Insufficiency - drug therapy | Retrospective Studies | Benzhydryl Compounds - therapeutic use | Diabetes Mellitus, Type 2 - complications | Drug Resistance | Kidney - physiopathology | Diabetic Nephropathies - urine | Hypoglycemic Agents - therapeutic use | Hyperglycemia - prevention & control | Kidney - drug effects | Sodium-Glucose Transporter 2 - metabolism | Diabetic Nephropathies - metabolism | Renal Insufficiency - metabolism | Biomarkers - blood | Disease Progression | Sodium-Glucose Transporter 2 - antagonists & inhibitors | Randomized Controlled Trials as Topic | Cross-Over Studies | Diabetes Mellitus, Type 2 - blood | Membrane Transport Modulators - therapeutic use | Renin-Angiotensin System - drug effects | Aged | Diabetes Mellitus, Type 2 - drug therapy | Type 2 diabetes | Medicine, Experimental | Medical records | Medical research | Glucose transporter | Excretion | Renin | Kidneys | Sodium | Angiotensin | Diabetes | Electronic medical records | Kidney transplantation | Index Medicus
Journal Article
Clinical Journal of the American Society of Nephrology, ISSN 1555-9041, 10/2017, Volume 12, Issue 10, pp. 1595 - 1600
Background and objectives: RRT and doubling of serum creatinine are considered the objective hard end points in nephrology intervention trials. Because both... 
Creatinine | Nephrology | Diabetes mellitus, type 2 | Humans | Diabetic nephropathies | Tetrazoles | Linear models | Kidney | Glomerular filtration rate | Irbesartan | Losartan | Renal dialysis | Renal replacement therapy | Angiotensin II | Biphenyl compounds | SERUM CREATININE | CHOICE | DECISION | GFR | UROLOGY & NEPHROLOGY | START | IRBESARTAN | NEPHROPATHY | PROGRESSION | DECLINE | Up-Regulation | Angiotensin II Type 1 Receptor Blockers - adverse effects | Renal Insufficiency, Chronic - etiology | Diabetic Nephropathies - etiology | Health Status Indicators | Angiotensin II Type 1 Receptor Blockers - therapeutic use | Biphenyl Compounds - adverse effects | Diabetic Nephropathies - drug therapy | Biphenyl Compounds - therapeutic use | Glomerular Filtration Rate - drug effects | Diabetic Nephropathies - physiopathology | Time Factors | Clinical Decision-Making | Endpoint Determination | Diabetes Mellitus, Type 2 - complications | Kidney - physiopathology | Kidney - drug effects | Risk Factors | Proportional Hazards Models | Linear Models | Treatment Outcome | Biomarkers - blood | Renal Insufficiency, Chronic - physiopathology | Disease Progression | Renal Insufficiency, Chronic - prevention & control | Diabetes Mellitus, Type 2 - physiopathology | Losartan - therapeutic use | Creatinine - blood | Losartan - adverse effects | Tetrazoles - therapeutic use | Clinical Trials as Topic - methods | Tetrazoles - adverse effects | Diabetes Mellitus, Type 2 - drug therapy | Health Status | Research Design | Renal Dialysis | Index Medicus | irbesartan | Diabetic Nephropathies | glomerular filtration rate | Renal Replacement Therapy | Biphenyl Compounds | nephrology | kidney | creatinine | Diabetes Mellitus, Type 2 | Original | renal dialysis
Journal Article
The Lancet Diabetes & Endocrinology, ISSN 2213-8587, 06/2019, Volume 7, Issue 6, pp. 415 - 417
Journal Article
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 08/2018, Volume 20, Issue 8, pp. 2019 - 2022
This study aimed to identify the optimal dose of the endothelin‐1 receptor antagonist atrasentan with maximal albuminuria reduction and minimal signs of sodium... 
pharmacokinetics | endothelin receptor antagonist | dose‐finding | pharmacodynamics | diabetic nephropathy | dose-finding | ENDOCRINOLOGY & METABOLISM | DIABETIC-NEPHROPATHY | AVOSENTAN | Biomarkers - urine | Humans | Body Weight - drug effects | Diabetic Nephropathies - drug therapy | Diabetic Nephropathies - blood | Sodium - metabolism | Dose-Response Relationship, Drug | Drug Therapy, Combination - adverse effects | Diabetic Nephropathies - physiopathology | Renal Insufficiency - physiopathology | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Endothelin A Receptor Antagonists - adverse effects | Renal Insufficiency - complications | Renal Insufficiency - drug therapy | Diabetes Mellitus, Type 2 - complications | Drug Resistance | Endothelin A Receptor Antagonists - therapeutic use | Diabetic Nephropathies - urine | Severity of Illness Index | Double-Blind Method | Endothelin A Receptor Antagonists - administration & dosage | Endothelin A Receptor Antagonists - pharmacokinetics | Biological Variation, Population | Renal Elimination - drug effects | Renal Insufficiency - metabolism | Albuminuria - prevention & control | Atrasentan - therapeutic use | Metabolic Clearance Rate - drug effects | Atrasentan - administration & dosage | Angiotensin Receptor Antagonists - therapeutic use | Atrasentan - adverse effects | Atrasentan - pharmacokinetics | Type 2 diabetes | Antimitotic agents | Medical research | Evaluation | Endothelin | Analysis | Diabetic nephropathies | Albumin | Medicine, Experimental | Antineoplastic agents | Creatinine | Kidneys | Sodium | Diabetes mellitus (non-insulin dependent) | Diabetes mellitus | Index Medicus | Brief Reports | Brief Report
Journal Article
Diabetes, obesity & metabolism, ISSN 1462-8902, 06/2019
To explore the added value of diabetes-related genetic risk scores to readily available clinical parameters in the prediction of HbA1c levels after initiation... 
Journal Article
Nephrology Dialysis Transplantation, ISSN 0931-0509, 06/2019, Volume 34, Issue Supplement_1
Journal Article
Nephrology Dialysis Transplantation, ISSN 0931-0509, 2018, Volume 33, Issue 12, pp. 2139 - 2145
Background. The kidney plays a central role in the regulation of vitamin D metabolism. It is not clear, however, whether vitamin D influences kidney function.... 
Albuminuria | Mendelian randomization | Vitamin D | Causality | Glomerular filtration rate | albuminuria | glomerular filtration rate | SERUM 25-HYDROXYVITAMIN D | vitamin D | DISEASE | UROLOGY & NEPHROLOGY | RISK | D LEVEL | causality | GENOME-WIDE ASSOCIATION | TRANSPLANTATION
Journal Article
Nephrology Dialysis Transplantation, ISSN 0931-0509, 04/2019, Volume 34, Issue 4, pp. 633 - 641
Abstract Background We aimed to determine if immune-unreactive albumin excretion (IURAE) is associated with cardiovascular (CV) events in a representative... 
cardiovascular events | MORTALITY | PRACTICE GUIDELINES | RISK-FACTORS | HPLC ASSAY | IMMUNONEPHELOMETRY | urinary albumin excretion | EXCRETION | TRANSPLANTATION | PERFORMANCE LIQUID-CHROMATOGRAPHY | immune-reactive albumin excretion | MICROALBUMINURIA | DISEASE | UROLOGY & NEPHROLOGY | HYPERTENSION
Journal Article
Current Opinion in Nephrology and Hypertension, ISSN 1062-4821, 07/2019, Volume 28, Issue 4, pp. 321 - 327
Journal Article
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, ISSN 0931-0509, 09/2018
Statins have shown multiple effects on different renal risk factors such as lowering of total cholesterol (TC) and lowering of urine protein:creatinine ratio... 
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 12/2018, Volume 20, Issue 12, pp. 2899 - 2904
Sodium retention and volume overload are the main determinants of poor response to renin‐angiotensin‐aldosterone system (RAAS) inhibition in patients with... 
clinical trial | cardiovascular disease | type 2 diabetes | diabetes complications | ANGIOTENSIN RECEPTOR BLOCKADE | ALBUMINURIA | HEART-FAILURE | NEPHROPATHY | BLOOD-PRESSURE | HYDROCHLOROTHIAZIDE | TRIAL | DIETARY-SODIUM RESTRICTION | ENDOCRINOLOGY & METABOLISM | END-POINTS | POST-HOC ANALYSIS | Predictive Value of Tests | Diabetic Nephropathies - etiology | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Male | Peptide Fragments - blood | Female | Drug Therapy, Combination | Diabetic Nephropathies - prevention & control | Diabetes Mellitus, Type 2 - complications | Natriuretic Peptide, Brain - blood | Hypoglycemic Agents - therapeutic use | Cardiovascular Diseases - etiology | Double-Blind Method | Fumarates - therapeutic use | Risk Factors | Treatment Outcome | Amides - therapeutic use | Biomarkers - blood | Antihypertensive Agents - therapeutic use | Diabetes Mellitus, Type 2 - blood | Renin-Angiotensin System - drug effects | Aged | Diabetes Mellitus, Type 2 - drug therapy | Type 2 diabetes | Complications and side effects | Diabetics | Chronic kidney failure | Angiotensin | Cardiovascular diseases | Aldosterone | Risk factors | Natriuretic peptides | Brain natriuretic peptide | Renin | Sodium | Peptides | Diabetes mellitus | Diabetes | Diabetes mellitus (non-insulin dependent) | Index Medicus | Brief Report | Brief Reports
Journal Article